169 related articles for article (PubMed ID: 14734014)
1. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta.
Bektic J; Berger AP; Pfeil K; Dobler G; Bartsch G; Klocker H
Eur Urol; 2004 Feb; 45(2):245-51; discussion 251. PubMed ID: 14734014
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.
Mizokami A; Gotoh A; Yamada H; Keller ET; Matsumoto T
J Urol; 2000 Sep; 164(3 Pt 1):800-5. PubMed ID: 10953159
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of isoflavones on prostate cancer cells and PTEN gene.
Cao F; Jin TY; Zhou YF
Biomed Environ Sci; 2006 Feb; 19(1):35-41. PubMed ID: 16673816
[TBL] [Abstract][Full Text] [Related]
4. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate.
Fritz WA; Wang J; Eltoum IE; Lamartiniere CA
Mol Cell Endocrinol; 2002 Jan; 186(1):89-99. PubMed ID: 11850125
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
[TBL] [Abstract][Full Text] [Related]
6. The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells.
Maggiolini M; Vivacqua A; Carpino A; Bonofiglio D; Fasanella G; Salerno M; Picard D; Andó S
Mol Pharmacol; 2002 Nov; 62(5):1027-35. PubMed ID: 12391264
[TBL] [Abstract][Full Text] [Related]
7. Designed modulation of sex steroid signaling inhibits telomerase activity and proliferation of human prostate cancer cells.
Verma V; Sharma V; Singh V; Sharma S; Bishnoi AK; Chandra V; Maikhuri JP; Dwivedi A; Kumar A; Gupta G
Toxicol Appl Pharmacol; 2014 Oct; 280(2):323-34. PubMed ID: 25123791
[TBL] [Abstract][Full Text] [Related]
8. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
9. Genistein alters growth factor signaling in transgenic prostate model (TRAMP).
Wang J; Eltoum IE; Lamartiniere CA
Mol Cell Endocrinol; 2004 Apr; 219(1-2):171-80. PubMed ID: 15149738
[TBL] [Abstract][Full Text] [Related]
10. Indole-3-carbinol inhibition of androgen receptor expression and downregulation of androgen responsiveness in human prostate cancer cells.
Hsu JC; Zhang J; Dev A; Wing A; Bjeldanes LF; Firestone GL
Carcinogenesis; 2005 Nov; 26(11):1896-904. PubMed ID: 15958518
[TBL] [Abstract][Full Text] [Related]
11. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
Arnold JT; Liu X; Allen JD; Le H; McFann KK; Blackman MR
Prostate; 2007 Aug; 67(11):1152-62. PubMed ID: 17503469
[TBL] [Abstract][Full Text] [Related]
13. Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells.
Lazarevic B; Karlsen SJ; Saatcioglu F
Oncol Rep; 2008 May; 19(5):1231-5. PubMed ID: 18425381
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
[TBL] [Abstract][Full Text] [Related]
15. Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells.
Davis JN; Kucuk O; Sarkar FH
Mol Carcinog; 2002 Jun; 34(2):91-101. PubMed ID: 12112315
[TBL] [Abstract][Full Text] [Related]
16. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms.
Tepper CG; Vinall RL; Wee CB; Xue L; Shi XB; Burich R; Mack PC; de Vere White RW
Prostate; 2007 Apr; 67(5):521-35. PubMed ID: 17252539
[TBL] [Abstract][Full Text] [Related]
17. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity.
Ouchi H; Ishiguro H; Ikeda N; Hori M; Kubota Y; Uemura H
Int J Urol; 2005 Jan; 12(1):73-80. PubMed ID: 15661057
[TBL] [Abstract][Full Text] [Related]
18. Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells.
He ML; Yuan HQ; Jiang AL; Gong AY; Chen WW; Zhang PJ; Young CY; Zhang JY
Cancer; 2006 Jun; 106(12):2547-55. PubMed ID: 16691616
[TBL] [Abstract][Full Text] [Related]
19. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells.
Dai JL; Maiorino CA; Gkonos PJ; Burnstein KL
Steroids; 1996 Sep; 61(9):531-9. PubMed ID: 8883219
[TBL] [Abstract][Full Text] [Related]
20. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
